Purpose: To describe the rate of COVID-19 in intravitreal injection (IVI) procedure at the onset of the pandemic.Methods: This transversal, observational and retrospective study included patients treated with IVI, in 3 groups. A: from February 20 to March 15, 2020, a period prior to lockdown and the first preventive measures against viral transmission. B: from March 16 to May 3, after the start of both, and C: from May 4 to June 19, after lockdown. Age, sex, diagnosis, drug, IVI laterality, visual acuity, percentage of single eyes, date of COVID-19 diagnosis, incidence among the Hospital attended population and number of COVID-19 patients admitted daily, were collected.Results: 1049 patients were treated, 564 (53.7%) on two or more occasions. COVID-19 rate was 1.51% (8/529) in group A, 0.21% (1/469) in B and 0% in C (0/926) (p=0.0001). The highest incidence peak x105 inhabitants and the mean daily admission rate, for the periods corresponding to the three groups, were 93.70/7.70 (SD 7.32), 418.72/27.83 (SD 24.68) and 24.58/2.28 (SD 1.97), respectively.Conclusion: The favourable trend in the COVID-19 rate among our patients, after implementing preventive measures against viral transmission, may assist in adequately planning IVI procedure in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.